Sentences with phrase «with androgen deprivation therapy»

A significant fraction of advanced PCa treated with androgen deprivation therapy experience relentless progression to lethal metastatic castration - resistant prostate cancer (mCRPC).

Not exact matches

«A significant number of advanced prostate cancer patients treated with a chemical castration therapy called androgen deprivation therapy (ADT) experience relapse with relentless progression to lethal metastatic, castration - resistant prostate cancer,» said Ronald DePinho, M.D., professor of Cancer Biology.

The authors focused on men newly diagnosed with localized (non-metastatic) prostate cancer in 1995 - 2011 and treated with radical prostatectomy, brachytherapy, radiation therapy, or primary androgen deprivation therapy (PADT).

Brachytherapy is an extremely efficient and safe radiation oncology modality, and this trial shows that it can have a wider field of applicability than simply in very localised and low risk tumours when combined with other techniques — in this case, androgen deprivation therapy and external bean radiation therapy.»

All had been treated previously with at least one type of androgen deprivation therapy and had rising levels of prostate specific antigen (PSA), a blood marker for prostate cancer, and radiographic evidence their cancers were becoming resistant.

Twenty - two patients with elevated prostate - specific antigen and biopsy - proven prostate carcinoma who underwent MRI of the prostate at 1.5 T with endorectal coil were divided into two groups: those who were treated with androgen deprivation, radiation therapy, or both, and a Gleason - matched control group who had not received such therapy.

Preliminary results of a study of patients with prostate cancer show that MR tractography may be a reliable quantitative imaging biomarker to assess prostate cancer treatment response to androgen deprivation and radiation therapy, according to a team of researchers at Brigham and Women's Hospital and Massachusetts General Hospital in Boston.

Androgen deprivation therapy (ADT) is a common treatment option for patients with advanced stage prostate cancer.

In current practice, men newly diagnosed with prostate cancer that has spread widely, and whose cancer depends on male hormones to grow, are started on hormone - blocking medications — androgen deprivation therapy (ADT).

Long - term follow - up of a large phase III study showed that chemohormonal therapy involving docetaxel added to androgen deprivation therapy (ADT) prolongs overall survival (OS) over ADT alone in metastatic hormone - sensitive prostate cancer (mHSPC) patients with high - volume disease.

Treatment with an investigational androgen receptor inhibitor significantly delayed the development of metastasis in patients with prostate cancer that had become resistant to standard androgen - deprivation therapy.

A second phase 3 study presented Sunday found that adding radiation to hormone therapy, also known as androgen - deprivation therapy (ADT) in patients with locally advanced or high - risk prostate cancer reduced the seven - year risk of dying by 43 percent compared to treating with hormone therapy alone.

With intermittent androgen deprivation, hormone therapy is given in cycles, with breaks between drug administrations, rather than continuouWith intermittent androgen deprivation, hormone therapy is given in cycles, with breaks between drug administrations, rather than continuouwith breaks between drug administrations, rather than continuously.